title: Comparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity C-reactive protein and oxidized low-density lipoprotein cholesterol in patients with type 2 diabetes mellitus.
abstract: The effect of ramipril (an angiotensin [AT]-converting enzyme inhibitor), telmisartan (an AT-II type 1 receptor blocker), or their combination on inflammation and lipid peroxidation was assessed in 37 patients with type 2 diabetes who were free of coronary artery disease. All regimens were associated with a significant reduction of C-reactive protein and oxidized low-density lipoprotein cholesterol serum levels (p <0.001). These results further enlighten the mechanisms underlying the cardiovascular beneficial effect of renin-AT system inhibition.
authors.affiliation: First Cardiology Department, Department of Endocrinology, Diabetes and Metabolism and Hematology Laboratory, Evangelismos Hospital, Athens, Greece. skoulouris@ath.forthnet.gr
authors.forename: Spyridon
authors.initials: S
authors.lastname: Koulouris
authors.forename: Phivos
authors.initials: P
authors.lastname: Symeonides
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Triantafyllou
authors.forename: Georgios
authors.initials: G
authors.lastname: Ioannidis
authors.forename: Ilias
authors.initials: I
authors.lastname: Karabinos
authors.forename: Theofanis
authors.initials: T
authors.lastname: Katostaras
authors.forename: Mahmud
authors.initials: M
authors.lastname: El-Ali
authors.forename: Theodoros
authors.initials: T
authors.lastname: Theodoridis
authors.forename: Ekaterini
authors.initials: E
authors.lastname: Vratsista
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Thalassinos
authors.forename: Vassiliki
authors.initials: V
authors.lastname: Kokkinou
authors.forename: Ioannis
authors.initials: I
authors.lastname: Nanas
authors.forename: Stamatios
authors.initials: S
authors.lastname: Stamatelopoulos
authors.forename: Pavlos
authors.initials: P
authors.lastname: Toutouzas
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D001565:Benzoates / Q000627:therapeutic use*; D002097:C-Reactive Protein / Q000032:analysis*; D008078:Cholesterol, LDL / Q000097:blood*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010084:Oxidation-Reduction; D017257:Ramipril / Q000627:therapeutic use*; D000077333:Telmisartan
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D001562:Benzimidazoles; D001565:Benzoates; D008078:Cholesterol, LDL; D002097:C-Reactive Protein; D017257:Ramipril; D000077333:Telmisartan